CASI Pharmaceuticals (CASI) Receiving Favorable Media Coverage, Study Shows
News headlines about CASI Pharmaceuticals (NASDAQ:CASI) have trended positive recently, AlphaOne Sentiment Analysis reports. The research firm, a division of Accern, rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. CASI Pharmaceuticals earned a news sentiment score of 0.45 on AlphaOne’s scale. AlphaOne also assigned media stories about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the immediate future.
CASI Pharmaceuticals (NASDAQ:CASI) traded down 1.86% during trading on Tuesday, hitting $1.19. The stock had a trading volume of 8,507 shares. CASI Pharmaceuticals has a 52 week low of $0.82 and a 52 week high of $1.76. The company has a 50-day moving average of $1.37 and a 200 day moving average of $1.35. The company’s market cap is $71.63 million.
CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings data on Friday, March 31st. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. On average, equities research analysts anticipate that CASI Pharmaceuticals will post ($0.24) EPS for the current year.
Separately, Maxim Group set a $4.00 target price on CASI Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, January 17th.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.